bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figures 3-5 Legends from Tyrosine Kinase Signaling in Clear Cell and Papillary Renal Cell Carcinoma Revealed by Mass Spectrometry–Based Phosphotyrosine Proteomics
Authors: Haake Scott M. , Li Jiannong , Bai Yun , Kinose Fumi , Fang Bin , Welsh Eric A. , Zent Roy , Dhillon Jasreman , Pow-Sang Julio M. , Chen Y. Ann , Koomen John M. , Rathmell W. Kimryn , Fishman Mayer , Haura Eric B.
Published: April 2023

Supplementary Figures 3-5 Legends
Supplementary Figures 3-4 from Tyrosine Kinase Signaling in Clear Cell and Papillary Renal Cell Carcinoma Revealed by Mass Spectrometry–Based Phosphotyrosine Proteomics
Authors: Haake Scott M. , Li Jiannong , Bai Yun , Kinose Fumi , Fang Bin , Welsh Eric A. , Zent Roy , Dhillon Jasreman , Pow-Sang Julio M. , Chen Y. Ann , Koomen John M. , Rathmell W. Kimryn , Fishman Mayer , Haura Eric B.
Published: April 2023

Internal (Supplementary Figure 3) and external (Supplementary Figure 4) tumor LC-MS/MS controls.
Supplementary figure 4 from TH-302 in Combination with Radiotherapy Enhances the Therapeutic Outcome and Is Associated with Pretreatment [18F]HX4 Hypoxia PET Imaging
Authors: Peeters Sarah G.J.A. , Zegers Catharina M.L. , Biemans Rianne , Lieuwes Natasja G. , van Stiphout Ruud G.P.M. , Yaromina Ala , Sun Jessica D. , Hart Charles P. , Windhorst Albert D. , van Elmpt Wouter , Dubois Ludwig J. , Lambin Philippe
Published: April 2023

Supplementary figure 4. Body weight was monitored during and after treatment for both rhabdomyosarcoma (A) and H460 (B) tumor-bearing animals. The change in body weight is represented in percentage. Data represent mean {plus minus} SEM.
Supplementary Figures 1-6 + Supplementary Tables 1-2 from Targeting MDM2 for Treatment of Adenoid Cystic Carcinoma
Authors: Warner Kristy A. , Nör Felipe , Acasigua Gerson A. , Martins Manoela D. , Zhang Zhaocheng , McLean Scott A. , Spector Matthew E. , Chepeha Douglas B. , Helman Joseph , Wick Michael J. , Moskaluk Christopher A. , Castilho Rogerio M. , Pearson Alexander T. , Wang Shaomeng , Nör Jacques E.
Published: April 2023

Table S1: (Table depicting patient demographics and tumor characteristics); Table S2: (Table depicting STR profiles of experimental models used here); Figure S1: (Characterization of UM-PDX-HACC-5, a PDX model of adenoid cystic carcinoma); Figure S2: (MI-773 induces ACC tumor regression); Figure S3: (MI-773 induces ACC tumor regression in an additional model of ACC); Figure S4: (Effect of MI-773 is p53-dependent); Figure S5: (Histopathology of UM-PDX-HACC-5 tumors treated with MI-773); Figure S6: (Aminoacid sequence of p53 in the ACC models used in this project)
Supplementary Table 2 from TH-302 in Combination with Radiotherapy Enhances the Therapeutic Outcome and Is Associated with Pretreatment [18F]HX4 Hypoxia PET Imaging
Authors: Peeters Sarah G.J.A. , Zegers Catharina M.L. , Biemans Rianne , Lieuwes Natasja G. , van Stiphout Ruud G.P.M. , Yaromina Ala , Sun Jessica D. , Hart Charles P. , Windhorst Albert D. , van Elmpt Wouter , Dubois Ludwig J. , Lambin Philippe
Published: April 2023

Supplementary Table 2. Time to reach 4 times start volume per treatment group for H460 bearing animals. Data represent mean {plus minus} SD, p-value and sensitization enhancement ratio.
Supplementary Table 1 from TH-302 in Combination with Radiotherapy Enhances the Therapeutic Outcome and Is Associated with Pretreatment [18F]HX4 Hypoxia PET Imaging
Authors: Peeters Sarah G.J.A. , Zegers Catharina M.L. , Biemans Rianne , Lieuwes Natasja G. , van Stiphout Ruud G.P.M. , Yaromina Ala , Sun Jessica D. , Hart Charles P. , Windhorst Albert D. , van Elmpt Wouter , Dubois Ludwig J. , Lambin Philippe
Published: April 2023

Supplementary Table 1. Time to reach 4 times start volume per treatment group for rhabdomyosarcoma bearing animals. Data represent mean {plus minus} SD, p-value and sensitization enhancement ratio.
Supplementary Table 1 from CMVpp65 Vaccine Enhances the Antitumor Efficacy of Adoptively Transferred CD19-Redirected CMV-Specific T Cells
Authors: Wang Xiuli , Wong ChingLam W. , Urak Ryan , Mardiros Armen , Budde Lihua E. , Chang Wen-Chung , Thomas Sandra H. , Brown Christine E. , La Rosa Corinna , Diamond Don J. , Jensen Michael C. , Nakamura Ryotaro , Zaia John A. , Forman Stephen J.
Published: April 2023

Supplementary Table 1. Selection of CMV-specific T cells
Supplementary Table 5 from Genetics and Prognostication in Splenic Marginal Zone Lymphoma: Revelations from Deep Sequencing
Authors: Parry Marina , Rose-Zerilli Matthew J.J. , Ljungström Viktor , Gibson Jane , Wang Jun , Walewska Renata , Parker Helen , Parker Anton , Davis Zadie , Gardiner Anne , McIver-Brown Neil , Kalpadakis Christina , Xochelli Aliki , Anagnostopoulos Achilles , Fazi Claudia , Gonzalez de Castro David , Dearden Claire , Pratt Guy , Rosenquist Richard , Ashton-Key Margaret , Forconi Francesco , Collins Andrew , Ghia Paolo , Matutes Estella , Pangalis Gerassimos , Stamatopoulos Kostas , Oscier David , Strefford Jonathan C.
Published: April 2023

Supplementary Table 5. Sanger screening of NOTCH2 exon 34
Supplementary Figure S1 from Systemic Correlates of White Adipose Tissue Inflammation in Early-Stage Breast Cancer
Authors: Iyengar Neil M. , Zhou Xi Kathy , Gucalp Ayca , Morris Patrick G. , Howe Louise R. , Giri Dilip D. , Morrow Monica , Wang Hanhan , Pollak Michael , Jones Lee W. , Hudis Clifford A. , Dannenberg Andrew J.
Published: April 2023

Supplementary Figure S1. White adipose tissue inflammation. A. CLS-B positive breast WAT. H&E (upper panel) and anti-CD68 immunostaining (lower panel); 40x (left panel) and 400x (right panel). Arrow indicates CLS-B. B. CLS-B negative breast WAT. H&E (upper panel) and anti-CD68 immunostaining (lower panel); 40x (left panel) and 400x (right panel). WAT, white adipose tissue; CLS-B, crown-like structures of the breast.
Supplemental table S3 from Dose Escalation of Tamoxifen in Patients with Low Endoxifen Level: Evidence for Therapeutic Drug Monitoring—The TADE Study
Authors: Fox Peter , Balleine Rosemary L. , Lee Clara , Gao Bo , Balakrishnar Bavanthi , Menzies Alexander M. , Yeap Shang Heng , Ali Sayed Sahanawaz , Gebski Val , Provan Pamela , Coulter Sally , Liddle Christopher , Hui Rina , Kefford Richard , Lynch Jodi , Wong Mark , Wilcken Nicholas , Gurney Howard
Published: April 2023

Endoxifen level for patients on moderate or strong CYP2D6 inhibitors
Supplemental Table and Figures from Poly (ADP-Ribose) Polymerase Inhibitor Hypersensitivity in Aggressive Myeloproliferative Neoplasms
Authors: Pratz Keith W. , Koh Brian D. , Patel Anand G. , Flatten Karen S. , Poh Weijie , Herman James G. , Dilley Robert , Harrell Maria I. , Smith B. Douglas , Karp Judith E. , Swisher Elizabeth M. , McDevitt Michael A. , Kaufmann Scott H.
Published: April 2023

Table S1: Primers for Methylation Analysis. Figure S1: Sensitivity of erythroid and myeloid progenitors to veliparib. Figure S2: Reproducibility of colony forming assays. Figure S3: Veliparib IC50 as a function of BRCA1 Promotor Methylation.
Supplementary Figure S2 from Mithramycin Depletes Specificity Protein 1 and Activates p53 to Mediate Senescence and Apoptosis of Malignant Pleural Mesothelioma Cells
Authors: Rao Mahadev , Atay Scott M. , Shukla Vivek , Hong Young , Upham Trevor , Ripley R. Taylor , Hong Julie A. , Zhang Mary , Reardon Emily , Fetsch Patricia , Miettinen Markku , Li Xinmin , Peer Cody J. , Sissung Tristan , Figg William D. , De Rienzo Assunta , Bueno Raphael , Schrump David S.
Published: April 2023

Overexpression of Sp1 in MPM specimens, and antitumor effect of mithramycin.
Supplementary Figure S1 from Mithramycin Depletes Specificity Protein 1 and Activates p53 to Mediate Senescence and Apoptosis of Malignant Pleural Mesothelioma Cells
Authors: Rao Mahadev , Atay Scott M. , Shukla Vivek , Hong Young , Upham Trevor , Ripley R. Taylor , Hong Julie A. , Zhang Mary , Reardon Emily , Fetsch Patricia , Miettinen Markku , Li Xinmin , Peer Cody J. , Sissung Tristan , Figg William D. , De Rienzo Assunta , Bueno Raphael , Schrump David S.
Published: April 2023

Overexpression of Sp1 and inhibition by mithramycin.
Acknowledgement from A Phase II, Randomized, Study of Weekly APG101+Reirradiation versus Reirradiation in Progressive Glioblastoma
Authors: Wick Wolfgang , Fricke Harald , Junge Klaus , Kobyakov Grigory , Martens Tobias , Heese Oliver , Wiestler Benedikt , Schliesser Maximilian G. , von Deimling Andreas , Pichler Josef , Vetlova Elena , Harting Inga , Debus Jürgen , Hartmann Christian , Kunz Claudia , Platten Michael , Bendszus Martin , Combs Stephanie E.
Published: April 2023

Acknowledgement. List of investigators and other study stuff at the individual sites.
Supplemental figures from HDAC Inhibition Induces MicroRNA-182, which Targets RAD51 and Impairs HR Repair to Sensitize Cells to Sapacitabine in Acute Myelogenous Leukemia
Authors: Lai Tsung-Huei , Ewald Brett , Zecevic Alma , Liu Chaomei , Sulda Melanie , Papaioannou Dimitrios , Garzon Ramiro , Blachly James S. , Plunkett William , Sampath Deepa
Published: April 2023

Supplemental Figure 1. HDAC inhibitors sensitize MV4-11 AML cells to CNDAC. Supplemental Figure 2. Action of CNDAC alone or in combination with 0.5 nM PS over time on Rad51 in MV4-11 cells. Supplemental Figure 3. Action of PS on Rad51 mRNA, Rad50 and Rad51 protein and lack of dependence on caspase-3 cleavage in the HDAC-mediated loss of Rad51 protein Supplemental Figure 4. HDAC inhibition does not decrease levels of the DNA repair proteins ATM or NBS1. Figure 5. HDAC inhibition does not increase levels of miR-182 in response to decitabine (DAC) alone. Figure 6. Recruitment of HDAC1 and HDAC2 at the miR-182 promoter in OCI-AML3 cells before and after exposure to 0.5 nM PS. Figure 7. OCI-.AML3 cells were left untreated, transfected with 100nM of scrambled oligonucleotides (Scr), miR-182 or anti-miR-182 for 48h (n=3) before a portion from each treatment was challenged with 0.5nM PS in combination with 2 μM CNDAC for 48h (n=2), following which the levels of cell death were assayed.
Supplementary Methods from Gemcitabine and CHK1 Inhibition Potentiate EGFR-Directed Radioimmunotherapy against Pancreatic Ductal Adenocarcinoma
Authors: Al-Ejeh Fares , Pajic Marina , Shi Wei , Kalimutho Murugan , Miranda Mariska , Nagrial Adnan M. , Chou Angela , Biankin Andrew V. , Grimmond Sean M. , Brown Michael P. , Khanna Kum Kum
Published: April 2023

Detailed methods of: EGFR immunohistochemistry of PDAC tissue microarrays Patient derived xenografts (PDXs) and cell lines (PDCLs) generation Cell culture Treatments in vitro Histological and immunoblotting analyses of PDXs post-treatment
Supplementary table 3 from A Novel Epigenetic Signature for Early Diagnosis in Lung Cancer
Authors: Diaz-Lagares Angel , Mendez-Gonzalez Jesus , Hervas David , Saigi Maria , Pajares Maria J. , Garcia Diana , Crujerias Ana B. , Pio Ruben , Montuenga Luis M. , Zulueta Javier , Nadal Ernest , Rosell Antoni , Esteller Manel , Sandoval Juan
Published: April 2023

Predictions of cancer using the epigenetic model for the 24 false negatives cytologies.
Supplementary Table 5 from PIK3CA Mutational Status in Circulating Tumor Cells Can Change During Disease Recurrence or Progression in Patients with Breast Cancer
Authors: Markou Athina , Farkona Sofia , Schiza Christina , Efstathiou Tonia , Kounelis Sophia , Malamos Nikos , Georgoulias Vassilis , Lianidou Evi
Published: April 2023

Suppl Table 5: PCR reaction mix for the detection of PIK3CA hotspot mutations in exon 9 and exon 20.
Supplementary Table 3 from PIK3CA Mutational Status in Circulating Tumor Cells Can Change During Disease Recurrence or Progression in Patients with Breast Cancer
Authors: Markou Athina , Farkona Sofia , Schiza Christina , Efstathiou Tonia , Kounelis Sophia , Malamos Nikos , Georgoulias Vassilis , Lianidou Evi
Published: April 2023

Sequences of primers and probes designed and used in this study.
Supplementary Table 2 from PIK3CA Mutational Status in Circulating Tumor Cells Can Change During Disease Recurrence or Progression in Patients with Breast Cancer
Authors: Markou Athina , Farkona Sofia , Schiza Christina , Efstathiou Tonia , Kounelis Sophia , Malamos Nikos , Georgoulias Vassilis , Lianidou Evi
Published: April 2023

Suppl. Table 2. Chemotherapy treatments for breast cancer patients with verified metastasis (n=57).
Supplemental Figure 3 from Systemic Tolerance Mediated by Melanoma Brain Tumors Is Reversible by Radiotherapy and Vaccination
Authors: Jackson Christopher M. , Kochel Christina M. , Nirschl Christopher J. , Durham Nicholas M. , Ruzevick Jacob , Alme Angela , Francica Brian J. , Elias Jimmy , Daniels Andrew , Dubensky Thomas W. , Lauer Peter , Brockstedt Dirk G. , Baxi Emily G. , Calabresi Peter A. , Taube Janis M. , Pardo Carlos A. , Brem Henry , Pardoll Drew M. , Lim Michael , Drake Charles G.
Published: April 2023

TGF-β blockade does not add to RT + vaccination. TGF-β blockade with 1D11 (A) or LY2157299 (B) does not extend survival when combined with RT + rLM-OVA in mice with B16-OVA brain tumors. (N= 10 animals / group).
The proteasome activities of LPACs and non-LPACs. from Cancer Stem-like Properties in Colorectal Cancer Cells with Low Proteasome Activity
Authors: Munakata Koji , Uemura Mamoru , Tanaka Shinji , Kawai Kenji , Kitahara Tomohiro , Miyo Masaaki , Kano Yoshihiro , Nishikawa Shinpei , Fukusumi Takahito , Takahashi Yusuke , Hata Taishi , Nishimura Junichi , Takemasa Ichiro , Mizushima Tsunekazu , Ikenaga Masakazu , Kato Takeshi , Murata Kohei , Carethers John M. , Yamamoto Hirofumi , Doki Yuichiro , Mori Masaki
Published: April 2023

The predominant proteasome activities (i.e., chymotrypsin-like activity, trypsin-like activity, and caspase-like activity) were significantly reduced in LPACs compared to non-LPACs. Chymotrypsin-like activity: HCT116 1.87Ã—104{plus minus}5.77Ã—102 vs. 6.53Ã—103{plus minus}5.86Ã—102 (p<0.0001), KM12SM 3.07Ã—104{plus minus}2.31Ã—103 vs. 6.60Ã—103{plus minus}4.00Ã—102 (p<0.0001). Trypsin-like activity: HCT116 3.63Ã—103 {plus minus}1.53Ã—102 vs. 1.67Ã—103{plus minus}5.77Ã—101 (p<0.0001), KM12SM 4.73Ã—103{plus minus}7.02Ã—102 vs. 1.53Ã—103{plus minus}5.77Ã—101 (p=0.0014). Caspase-like activity: HCT116 1.17Ã—104 {plus minus}5.77Ã—102 vs. 4.33Ã—103{plus minus}2.08Ã—102 (p<0.0001), KM12SM 1.17Ã—104 {plus minus}5.77Ã—102 vs. 2.77Ã—103{plus minus}1.15Ã—102 (p<0.0001). The data are presented as mean{plus minus}standard deviation (SD). * p<0.05.
The confirmation of stable ZsGreen expression in CRC cell lines. from Cancer Stem-like Properties in Colorectal Cancer Cells with Low Proteasome Activity
Authors: Munakata Koji , Uemura Mamoru , Tanaka Shinji , Kawai Kenji , Kitahara Tomohiro , Miyo Masaaki , Kano Yoshihiro , Nishikawa Shinpei , Fukusumi Takahito , Takahashi Yusuke , Hata Taishi , Nishimura Junichi , Takemasa Ichiro , Mizushima Tsunekazu , Ikenaga Masakazu , Kato Takeshi , Murata Kohei , Carethers John M. , Yamamoto Hirofumi , Doki Yuichiro , Mori Masaki
Published: April 2023

Stable transfection was confirmed by treatment with MG132 for 24 hours. Transfected cells showed stable expression in over 90% (below). Bar: 20Î¼m.
LPACs were not detected transitioning from non-LPACs. from Cancer Stem-like Properties in Colorectal Cancer Cells with Low Proteasome Activity
Authors: Munakata Koji , Uemura Mamoru , Tanaka Shinji , Kawai Kenji , Kitahara Tomohiro , Miyo Masaaki , Kano Yoshihiro , Nishikawa Shinpei , Fukusumi Takahito , Takahashi Yusuke , Hata Taishi , Nishimura Junichi , Takemasa Ichiro , Mizushima Tsunekazu , Ikenaga Masakazu , Kato Takeshi , Murata Kohei , Carethers John M. , Yamamoto Hirofumi , Doki Yuichiro , Mori Masaki
Published: April 2023

Non-LPACs were observed after each treatment, 5-FU, L-OHP and radiation (8Gy), at 0 hour, 24 hours, 48 hours and 72 hours. Non-LPACs never changed to LPACs in each assay. Bar: 100Î¼m.
Supplemental Figure S1 from Whole Exome Sequencing Reveals the Order of Genetic Changes during Malignant Transformation and Metastasis in a Single Patient with NF1-plexiform Neurofibroma
Authors: Hirbe Angela C. , Dahiya Sonika , Miller Christopher A. , Li Tiandao , Fulton Robert S. , Zhang Xiaochun , McDonald Sandra , DeSchryver Katherine , Duncavage Eric J. , Walrath Jessica , Reilly Karlyne M. , Abel Haley J. , Pekmezci Melike , Perry Arie , Ley Timothy J. , Gutmann David H.
Published: April 2023

Supplemental Figure S1. JW18 was derived from a mouse MPNST. Hematoxylin & eosin staining of the JW18 parent tumor shows long fascicles, plump oblong nuclei, and mitotic figures (A). JW18 cells are immunopositive for S100 (B), but are negative for the muscle markers MyoD1 and Myf4 (C and D). Positive staining controls for MyoD1 and Myf4 are shown for the rhabdomyosarcoma line (E and F). Immunopositive cells are green, while the DAPI nuclear stain is blue.
Supplementary Figure S1 from A Phase III Clinical Trial of the Epidermal Growth Factor Vaccine CIMAvax-EGF as Switch Maintenance Therapy in Advanced Non–Small Cell Lung Cancer Patients
Authors: Rodriguez Pedro C. , Popa Xitllaly , Martínez Odeth , Mendoza Silvia , Santiesteban Eduardo , Crespo Tatiana , Amador Rosa M. , Fleytas Ricardo , Acosta Soraida C. , Otero Yanine , Romero Gala N. , de la Torre Ana , Cala Mireysi , Arzuaga Lina , Vello Loisel , Reyes Delmairis , Futiel Niurka , Sabates Teresa , Catala Mauricio , Flores Yoanna I. , Garcia Beatriz , Viada Carmen , Lorenzo-Luaces Patricia , Marrero Maria A. , Alonso Liuba , Parra Jenelin , Aguilera Nadia , Pomares Yaisel , Sierra Patricia , Rodríguez Gryssell , Mazorra Zaima , Lage Agustin , Crombet Tania , Neninger Elia
Published: April 2023

CONSORT Diagram (PP = Per Protocol Population).
Supplemental tables 1 - 5 from Identification of Differentially Expressed Long Noncoding RNAs in Bladder Cancer
Authors: Peter Stefan , Borkowska Edyta , Drayton Ross M. , Rakhit Callum P. , Noon Aidan , Chen Wei , Catto James WF
Published: April 2023

Supplemental tables 1 - 5. Supplemental tables reporting lncRNA microarray data, and details including gene ontology for selected candidates.
Supplementary Figure Legends from Dual mTORC1/2 Blockade Inhibits Glioblastoma Brain Tumor Initiating Cells In Vitro and In Vivo and Synergizes with Temozolomide to Increase Orthotopic Xenograft Survival
Authors: Luchman H. Artee , Stechishin Owen D.M. , Nguyen Stephanie A. , Lun Xueqing Q. , Cairncross J. Gregory , Weiss Samuel
Published: April 2023

Supplementary Figure Legends from Dual mTORC1/2 Blockade Inhibits Glioblastoma Brain Tumor Initiating Cells In Vitro and In Vivo and Synergizes with Temozolomide to Increase Orthotopic Xenograft Survival
Supplementary Figure 6 from Dual mTORC1/2 Blockade Inhibits Glioblastoma Brain Tumor Initiating Cells In Vitro and In Vivo and Synergizes with Temozolomide to Increase Orthotopic Xenograft Survival
Authors: Luchman H. Artee , Stechishin Owen D.M. , Nguyen Stephanie A. , Lun Xueqing Q. , Cairncross J. Gregory , Weiss Samuel
Published: April 2023

Pharmacological inhibition of EGFR and PI3K/mTORC1/2 signaling in BTICs.
Supplementary Figure 5 from Dual mTORC1/2 Blockade Inhibits Glioblastoma Brain Tumor Initiating Cells In Vitro and In Vivo and Synergizes with Temozolomide to Increase Orthotopic Xenograft Survival
Authors: Luchman H. Artee , Stechishin Owen D.M. , Nguyen Stephanie A. , Lun Xueqing Q. , Cairncross J. Gregory , Weiss Samuel
Published: April 2023

Oral administration of AZD is compatible with TMZ chemotherapy in vivo.
Supplementary Figures 1-5, Supplementary Table 1 from A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells
Authors: Gullà Annamaria , Di Martino Maria Teresa , Gallo Cantafio Maria Eugenia , Morelli Eugenio , Amodio Nicola , Botta Cirino , Pitari Maria Rita , Lio Santo Giovanni , Britti Domenico , Stamato Maria Angelica , Hideshima Teru , Munshi Nikhil C. , Anderson Kenneth C. , Tagliaferri Pierosandro , Tassone Pierfrancesco
Published: April 2023

Fig. S1. MiR-221 and miR-222 expression levels in Melphalan resistant MM U266/LR7 and sensitive U266/S; Fig. S2. Enforced expression of miR-221/222 decreases melphalan sensitivity of MM cells in vitro; Fig. S3. MiR-221/222 expression levels in Melphalan resistant MM U266/LR7 adherent to human Hs-5; Fig. S4. Genome-wide expression patterns associated with miR-221/222 inhibitors plus melphalan treatment; Fig. S5. Validation by q-RT-PCR of gene expression results; Table S1. Synergistic index of combination treatment with miR-221/222 inhibitors plus Melphalan.
Supplementary Figure 1-6, Supplementary Tables 1-3 from PHLPP2 Downregulation Contributes to Lung Carcinogenesis Following B[a]P/B[a]PDE Exposure
Authors: Huang Haishan , Pan Xiaofu , Jin Honglei , Li Yang , Zhang Lin , Yang Caili , Liu Pei , Liu Ya , Chen Lili , Li Jingxia , Zhu Junlan , Zeng Xingruo , Fu Kai , Chen Guorong , Gao Jimin , Huang Chuanshu
Published: April 2023

Supplementary Figure 1-6, Supplementary Tables 1-3. Supplementary Table 1 Clinic pathologic characteristics of 54 cases of lung cancer patients; Supplementary Table 2 The number of mouse for TNFa expression quantitative analysis; Supplementary Table 3 TNFa is crucial for B[a]P-induced lung carcinogenic effect in vivo; Figure S1 miR-494 was not involved in B[a]P/B[a]PDE induced PHLPP2 downregulation; Figure S2 miR-205 regulated AP-1-mediated TNFa transcription; Figure S3 B[a]P induced lung inflammatory responses and carcinoma in wild-type and TNFa-/-mice; Figure S4 lung carcinoma formation in C57BL/6J wild type mice following B[a]P exposure; Figure S5 PHLPP2 downregulation in TNFa knockdown Beas-2B cells and C57BL/6J TNFa-/- mice following B[a]P/B[a]PDE exposure; Figure S6 Illustration of molecular mechanisms leading to Lung carcinogenesis following B[a]P exposure.
Supplemental Figure 1 from Targeting IL11 Receptor in Leukemia and Lymphoma: A Functional Ligand-Directed Study and Hematopathology Analysis of Patient-Derived Specimens
Authors: Karjalainen Katja , Jaalouk Diana E. , Bueso-Ramos Carlos , Bover Laura , Sun Yan , Kuniyasu Akihiko , Driessen Wouter H.P. , Cardó-Vila Marina , Rietz Cecilia , Zurita Amado J. , O'Brien Susan , Kantarjian Hagop M. , Cortes Jorge E. , Calin George A. , Koivunen Erkki , Arap Wadih , Pasqualini Renata
Published: April 2023

Supplemental Figure 1. Cell surface expression of IL-11R in AML patient derived samples and hematopoietic cells from healthy bone marrow as analyzed by flow cytometry.
Figure S3 from Identification of Recurrent FGFR3–TACC3 Fusion Oncogenes from Lung Adenocarcinoma
Authors: Capelletti Marzia , Dodge Michael E. , Ercan Dalia , Hammerman Peter S. , Park Seung-Il , Kim Jhingook , Sasaki Hidefumi , Jablons David M. , Lipson Doron , Young Lauren , Stephens Phil J. , Miller Vincent A. , Lindeman Neal I. , Munir Kiara J. , Richards William G. , Jänne Pasi A.
Published: April 2023

Figure S3. A. Agarose gel separation of the FGFR3-TACC3 fusion specific RT-PCR amplicons. H3122 contains an EML4-ALK fusion, PC9 contains an EGFR mutation (del E746_A750) and A549 harboring a KRAS mutation. These cell lines are used as negative controls. The sample K2-49 shows two bands corresponding to two different variants of the fusion, the higher one between FGFR3 exon 17 and TACC3 exon4 and the lower one between the same exon of FGFR3 and the exon 11 of TACC3. Sample J2-109 shows a predominant variant connecting exon 17 of FGFR3 and exon 8 of TACC3 and the lowest corresponding to a fusion between FGFR3 exon 17 and TACC3 exon 11. The CG-42 sample shows only one variant fusing together FGFR3 exon 17 and TACC3 exon 10. B. Sequencing chromatogram of the different FGFR3-TACC3 variants detected in the three patients.
Figure S1 from Identification of Recurrent FGFR3–TACC3 Fusion Oncogenes from Lung Adenocarcinoma
Authors: Capelletti Marzia , Dodge Michael E. , Ercan Dalia , Hammerman Peter S. , Park Seung-Il , Kim Jhingook , Sasaki Hidefumi , Jablons David M. , Lipson Doron , Young Lauren , Stephens Phil J. , Miller Vincent A. , Lindeman Neal I. , Munir Kiara J. , Richards William G. , Jänne Pasi A.
Published: April 2023

Figure S1. Sequencing chromatogram of the two RIT1mutations identified. A. D51Y mutation identified in sample J2-113, occurring in the Switch I domain in the RIT1 gene. B. M90V mutation identified in sample CG-67, occurring in the Switch II domain of the RIT1 gene.
Supplemental figure 1 from Clinical and Molecular Characteristics of NF1-Mutant Lung Cancer
Authors: Redig Amanda J. , Capelletti Marzia , Dahlberg Suzanne E. , Sholl Lynette M. , Mach Stacy , Fontes Caitlin , Shi Yunling , Chalasani Poornima , Jänne Pasi A.
Published: April 2023

Gene mutations evaluated in 275 gene panel referenced in the manuscript.
Supplementary Figure 1 from Expression, Clinical Significance, and Receptor Identification of the Newest B7 Family Member HHLA2 Protein
Authors: Janakiram Murali , Chinai Jordan M. , Fineberg Susan , Fiser Andras , Montagna Cristina , Medavarapu Ramadevi , Castano Ekaterina , Jeon Hyungjun , Ohaegbulam Kim C. , Zhao Ruihua , Zhao Aimin , Almo Steven C. , Sparano Joseph A. , Zang Xingxing
Published: April 2023

Supplementary Figure 1: Stained controls from IHC protocol development.
Supplementary Tables 1-5 from Development and Validation of a Gene Profile Predicting Benefit of Postmastectomy Radiotherapy in Patients with High-Risk Breast Cancer: A Study of Gene Expression in the DBCG82bc Cohort
Authors: Tramm Trine , Mohammed Hayat , Myhre Simen , Kyndi Marianne , Alsner Jan , Børresen-Dale Anne-Lise , Sørlie Therese , Frigessi Arnoldo , Overgaard Jens
Published: April 2023

Supplementary Table 1: Distribution of clinico-pathological parameters among 112 patients included in the validation set. Supplementary Table 2: Assays and primers used for testing gene profile. Supplementary Table 3: Distribution of clinico-pathological parameters among 146 patients of the training set. Supplementary Table 4: Characteristics of patients included in and excluded from the technical transfer of the DBCG-RT profile to RT-qPCR and formalin fixed, paraffin embedded tissue (FFPE). Supplementary Table 5: Distribution of patients with "High LRR risk" and "Low LRR risk" within subgroups of clinical relevance for administration of PMRT.
Supplementary Data from Interrogating Two Schedules of the AKT Inhibitor MK-2206 in Patients with Advanced Solid Tumors Incorporating Novel Pharmacodynamic and Functional Imaging Biomarkers
Authors: Yap Timothy A. , Yan Li , Patnaik Amita , Tunariu Nina , Biondo Andrea , Fearen Ivy , Papadopoulos Kyriakos P. , Olmos David , Baird Richard , Delgado Liliana , Tetteh Ernestina , Beckman Robert A. , Lupinacci Lisa , Riisnaes Ruth , Decordova Shaun , Heaton Simon P. , Swales Karen , deSouza Nandita M. , Leach Martin O. , Garrett Michelle D. , Sullivan Daniel M. , de Bono Johann S. , Tolcher Anthony W.
Published: April 2023

Supplementary Data. Supplementary Methods, Supplementary Tables and Supplementary Figures (Unmarked)
Supplementary Figure 3 from Development and Validation of a Gene Profile Predicting Benefit of Postmastectomy Radiotherapy in Patients with High-Risk Breast Cancer: A Study of Gene Expression in the DBCG82bc Cohort
Authors: Tramm Trine , Mohammed Hayat , Myhre Simen , Kyndi Marianne , Alsner Jan , Børresen-Dale Anne-Lise , Sørlie Therese , Frigessi Arnoldo , Overgaard Jens
Published: April 2023

Cumulative incidence plots showing "High LRR risk" patients of the training set stratified according to PMRT and tumorsize (A), lymph node positive status (B), ER status (C) and combinations of tumorsize and nodal status (D), respectively.
Supplemetal Figures Legend from Tumor-Suppressive miR148a Is Silenced by CpG Island Hypermethylation in IDH1-Mutant Gliomas
Authors: Li Sichen , Chowdhury Reshmi , Liu Fei , Chou Arthur P. , Li Tie , Mody Reema R. , Lou Jerry J. , Chen Weidong , Reiss Jean , Soto Horacio , Prins Robert , Liau Linda M. , Mischel Paul S. , Nghiemphu Phioanh L. , Yong William H. , Cloughesy Timothy F. , Lai Albert
Published: April 2023

Supplemental Figures Legend
Supplementary Tables S1-11 from Tumor-Suppressive miR148a Is Silenced by CpG Island Hypermethylation in IDH1-Mutant Gliomas
Authors: Li Sichen , Chowdhury Reshmi , Liu Fei , Chou Arthur P. , Li Tie , Mody Reema R. , Lou Jerry J. , Chen Weidong , Reiss Jean , Soto Horacio , Prins Robert , Liau Linda M. , Mischel Paul S. , Nghiemphu Phioanh L. , Yong William H. , Cloughesy Timothy F. , Lai Albert
Published: April 2023

Supplementary Tables S1-11. Supplementary Table S1. Patient demographics of the RRBS discovery set. Supplementary Table S2. RRBS Mean Coverage per sample. Supplementary Table S3. RRBS coverage of CpG islands associated with miRNAs. Supplementary Table S4. Hypermethylated CpG islands within 5000 bp of miRNAs in IDH1MUT versus IDH1/2WT gliomas (G-CIMP). Supplementary Table S5. Targeted bisulfite sequencing results for miR-148a associated CpG island (Region 1). Supplementary Table S6. Targeted bisulfite sequencing results for miR-148a associated CpG island (Region 2). Supplementary Table S7. Demographics and miR-148a methylation status of GBM and Grade III glioma patient cohort. Supplementary Table S8. Univariate and Multivariate Cox Proportional Hazards Analysis of Factors Affecting OS in GBM and Grade III gliomas. Supplementary Table S9. Predicted miR-148a targets. Supplementary Table S10. Bisulfite sequencing primer sets. Supplementary Table S11. Methylation Specific PCR (MSP) primer sets.
Supplemental Methods, Figures 1-2, Table S1 from Standardized Ki67 Diagnostics Using Automated Scoring—Clinical Validation in the GeparTrio Breast Cancer Study
Authors: Klauschen Frederick , Wienert Stephan , Schmitt Wolfgang D. , Loibl Sibylle , Gerber Bernd , Blohmer Jens-Uwe , Huober Jens , Rüdiger Thomas , Erbstößer Erhard , Mehta Keyur , Lederer Bianca , Dietel Manfred , Denkert Carsten , von Minckwitz Gunter
Published: April 2023

Supplemental Methods, Figures 1-2, Table S1. Supplemental Methods providing details on the study cohort and the image analysis algorithm. Supp. Figure 1: A) Ki67 stained breast cancer tissue. B) Haematoxylin Signal derived from color deconvolution (1) and C) histogram showing frequencies (y axis) of specific heamatoxylin intensities (x axis) of the image background (red) and foreground (green). Arrows show representative locations of different intensity classes: no tissue (red), tissue but no cell nuclei (blue), Ki67 negative cell (green) and Ki67 positive cell nuclei (orange). Figure 2: Construction of the borderline between plausible and non-plausible thresholds by combining the threshold and the resulting ratio of positive cells. Supplementary table S1: Clinico-pathological data of the study cohort
Supplementary Materials from Phase I Trial of Bortezomib (PS-341; NSC 681239) and “Nonhybrid” (Bolus) Infusion Schedule of Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory Indolent B-cell Neoplasms
Authors: Holkova Beata , Kmieciak Maciej , Perkins E. Brent , Bose Prithviraj , Baz Rachid C. , Roodman G. David , Stuart Robert K. , Ramakrishnan Viswanathan , Wan Wen , Peer Cody J. , Dawson Jana , Kang Loveleen , Honeycutt Connie , Tombes Mary Beth , Shrader Ellen , Weir-Wiggins Caryn , Wellons Martha , Sankala Heidi , Hogan Kevin T. , Colevas A. Dimitrios , Doyle L. Austin , Figg William D. , Coppola Domenico , Roberts John D. , Sullivan Daniel , Grant Steven
Published: April 2023

Supplementary Materials. Supplemental Table 1. C1D1 alvocidib pharmacokinetics by dose Supplemental Figure 1. Sample alvocidib concentration-time profile. Samples were obtained pre-infusion, immediately following infusion, and at 1, 2, 4, 8, 12, and 24 hours post-infusion.
Supplemental Figure 1 from DNA Methylation Profiling in Pheochromocytoma and Paraganglioma Reveals Diagnostic and Prognostic Markers
Authors: de Cubas Aguirre A. , Korpershoek Esther , Inglada-Pérez Lucia , Letouzé Eric , Currás-Freixes Maria , Fernández Agustin F. , Comino-Méndez Iñaki , Schiavi Francesca , Mancikova Veronika , Eisenhofer Graeme , Mannelli Massimo , Opocher Guiseppe , Timmers Henri , Beuschlein Felix , de Krijger Ronald , Cascon Alberto , Rodríguez-Antona Cristina , Fraga Mario F. , Favier Judith , Gimenez-Roqueplo Anne-Paule , Robledo Mercedes
Published: April 2023

Supplemental Figure 1. PNMT gene methylation in PPGL.
Supplemental Tables 1-5 from Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia
Authors: Cervantes-Gomez Fabiola , Lamothe Betty , Woyach Jennifer A. , Wierda William G. , Keating Michael J. , Balakrishnan Kumudha , Gandhi Varsha
Published: April 2023

Supplemental Tables 1-5. Table S1: Antibody for immunoblots and Primers for RT-PCR assays and their sources are listed; Table S2: Drug-mediated ex-vivo induction of cell death in residual circulating CLL cells obtained from the peripheral blood of patients after 4 weeks of ibrutinib therapy; Table S3: Patient Characteristics; Table S4: Induction of CLL cell death after ex-vivo treatment of lymphocytes obtained from peripheral blood of patients after 2, 4, or 12 weeks of ibrutinib treatment; Table S5: ABT-737- and ABT-199-induced cell death after ex-vivo treatment of CLL lymphocytes obtained from patients at 0, 4, and 12 weeks of ibrutinib therapy.
Supplemental Materials, Supplementary Tables 1-3 from A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced Cancer
Authors: Patnaik Amita , Haluska Paul , Tolcher Anthony W. , Erlichman Charles , Papadopoulos Kyriakos P. , Lensing Janet L. , Beeram Muralidhar , Molina Julian R. , Rasco Drew W. , Arcos Rebecca R. , Kelly Claudia S. , Wijayawardana Sameera R. , Zhang Xuekui , Stancato Louis F. , Bell Robert , Shi Peipei , Kulanthaivel Palaniappan , Pitou Celine , Mulle Lynette B. , Farrington Daphne L. , Chan Edward M. , Goetz Matthew P.
Published: April 2023

Table S1:Summary of baseline pathological diagnosis; Table S2:Noncompartmental Pharmacokinetic Summary Following Oral Administration of ralimetinib on Day 1 and on Day 14 (Cycle 1) - Capsule Formulation; Table S3: Noncompartmental Pharmacokinetic Summary Following Oral Administration of ralimetinib on Day 1 and on Day 14 (Cycle 1) - Tablet Formulation
Supplemental Figure S1 from A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced Cancer
Authors: Patnaik Amita , Haluska Paul , Tolcher Anthony W. , Erlichman Charles , Papadopoulos Kyriakos P. , Lensing Janet L. , Beeram Muralidhar , Molina Julian R. , Rasco Drew W. , Arcos Rebecca R. , Kelly Claudia S. , Wijayawardana Sameera R. , Zhang Xuekui , Stancato Louis F. , Bell Robert , Shi Peipei , Kulanthaivel Palaniappan , Pitou Celine , Mulle Lynette B. , Farrington Daphne L. , Chan Edward M. , Goetz Matthew P.
Published: April 2023

Trial Profile
Supplemental Figure 1 from Human Anaplastic Thyroid Carcinoma Cells Are Sensitive to NK Cell–Mediated Lysis via ULBP2/5/6 and Chemoattract NK Cells
Authors: Wennerberg Erik , Pfefferle Aline , Ekblad Lars , Yoshimoto Yuya , Kremer Veronika , Kaminskyy Vitaliy O , Juhlin C Christofer , Höög Anders , Bodin Inger , Svjatoha Vitalijs , Larsson Catharina , Zedenius Jan , Wennerberg Johan , Lundqvist Andreas
Published: April 2023

Supplemental Figure 1. (A) Annexin V/7AAD viability staining of ATC cells (U-Hth 104 cell line), non-malignant thyroid cells(non-toxic goiter), immortalized fibroblast cells (BJ cell line) autologous B cells and T cells cultured with or without expanded NK cells at a 1:1 ratio for 4 h. (B) Mean fluorescence intensity (MFI) of NKG2D-ligands on viable tumor cells from ATC FNA. MFI values from NKG2D-ligand staining have been subtracted with isotype control MFI values (C) Specific lysis of the ATC cell line LUTC-17 by autologous NK cells in a 5h cytotoxicity assay. Blocking antibodies targeting ULBP2 or NKG2D was added 30 minutes prior and during the cytotoxicity assay. Effector-to-target ratio = 2:1. The experiment was performed once.
Supplementary Figures 1-2 from K562-Derived Whole-Cell Vaccine Enhances Antitumor Responses of CAR-Redirected Virus-Specific Cytotoxic T Lymphocytes In Vivo
Authors: Caruana Ignazio , Weber Gerrit , Ballard Brandon C. , Wood Michael S. , Savoldo Barbara , Dotti Gianpietro
Published: April 2023

Supplementary Figures 1-2. Supplementary Figure 1. Expression of CD80, CD83, CD11c and HLA-DR by monocytes 72 hours after co-culture with irradiated K/pp65 (in blue), K/OX40L/pp65 (in violet), K/CD40L/pp65 (in orange) and K/OX40L/CD40L/pp65 (in green); Supplementary Figure 2. Cytotoxic activity (51Cr-release assay at 40:1, 20:1, 10:1 and 5:1 effector:target ratios) of CAR-CMV-CTLs stimulated in vitro by K/pp65 or K/CD40L/pp65 or K/CD40L/OX40L/pp65.
Supplemental Video M1 from A Systematic Comparison of 18F-C-SNAT to Established Radiotracer Imaging Agents for the Detection of Tumor Response to Treatment
Authors: Witney Timothy H. , Hoehne Aileen , Reeves Robert E. , Ilovich Ohad , Namavari Mohammad , Shen Bin , Chin Frederick T. , Rao Jianghong , Gambhir Sanjiv S.
Published: April 2023

Supplemental Video M1. 18FFDG uptake in naive tumors
Supplementary Figure 1 Legend from The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies
Authors: Niederst Matthew J. , Hu Haichuan , Mulvey Hillary E. , Lockerman Elizabeth L. , Garcia Angel R. , Piotrowska Zofia , Sequist Lecia V. , Engelman Jeffrey A.
Published: April 2023

Supplementary Figure 1 Legend. Describing the qPCR assay and variant allele frequency data that are included in the figure.
supplementary figures from Pharmacodynamic Response of the MET/HGF Receptor to Small-Molecule Tyrosine Kinase Inhibitors Examined with Validated, Fit-for-Clinic Immunoassays
Authors: Srivastava Apurva K. , Hollingshead Melinda G. , Weiner Jennifer , Navas Tony , Evrard Yvonne A. , Khin Sonny A. , Ji Jiuping Jay , Zhang Yiping , Borgel Suzanne , Pfister Thomas D. , Kinders Robert J. , Bottaro Donald P. , Linehan W. Marston , Tomaszewski Joseph E. , Doroshow James H. , Parchment Ralph E.
Published: April 2023

Figure S1: Specificity of the MET antibodies demonstrated by Western blot analysis. Figure S2: Effect of freeze-thaw cycles and warm vs cold ischemia time on full-length and pMET levels. Figure S3: Inhibition of tumor growth and intratumoral MET phosphorylation by PHA665752 in the GTL-16 human gastric cancer model. Figure S4: Comparison of pMET:full-length MET ratios in vehicle- and PF02341066-treated SNU5 xenografts. Figure S5: Absolute MET levels decrease during SNU5 tumor growth due to mouse cell infiltration. Figure S6: Purification of rMET protein for use as an assay calibrator. Figure S7: Longitudinal values of MET and the pY1235-MET:MET ratio during growth of vehicle treated GTL-16 tumors. Figure S8: MET expression determined by immunoblot in fresh flash-frozen mouse liver and muscle tissues.
Supplementary Figures 1, 2 from Broad, Hybrid Capture–Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches
Authors: Drilon Alexander , Wang Lu , Arcila Maria E. , Balasubramanian Sohail , Greenbowe Joel R. , Ross Jeffrey S. , Stephens Phil , Lipson Doron , Miller Vincent A. , Kris Mark G. , Ladanyi Marc , Rizvi Naiyer A.
Published: April 2023

Supplementary Figure 1. Distribution of median exon coverage depths for the samples included in this study, all passing the minimum threshold of 250x with an average median exon coverage depth >700x. Supplementary Figure 2. Median exon coverage depth and percent of exons >100x for 34 samples included in this study.
Supplemental Figure Legends from IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function
Authors: Vallera Daniel A. , Felices Martin , McElmurry Ron , McCullar Valarie , Zhou Xianzheng , Schmohl Joerg Uwe , Zhang Bin , Lenvik Alexander J. , Panoskaltsis-Mortari Angela , Verneris Michael R. , Tolar Jakub , Cooley Sarah , Weisdorf Daniel J. , Blazar Bruce R. , Miller Jeffrey S.
Published: April 2023

Supplemental Figure Legends
Supplementary Table S1 from Adoptive Transfer of MAGE-A4 T-cell Receptor Gene-Transduced Lymphocytes in Patients with Recurrent Esophageal Cancer
Authors: Kageyama Shinichi , Ikeda Hiroaki , Miyahara Yoshihiro , Imai Naoko , Ishihara Mikiya , Saito Kanako , Sugino Sahoko , Ueda Shugo , Ishikawa Takeshi , Kokura Satoshi , Naota Hiroaki , Ohishi Kohshi , Shiraishi Taizo , Inoue Naoki , Tanabe Masashige , Kidokoro Tomohide , Yoshioka Hirofumi , Tomura Daisuke , Nukaya Ikuei , Mineno Junichi , Takesako Kazutoh , Katayama Naoyuki , Shiku Hiroshi
Published: April 2023

Peptides which have homologue sequences with MAGE-A4143-151 peptide.
Supplementary Methods from Genetic Evolution of T-cell Resistance in the Course of Melanoma Progression
Authors: Sucker Antje , Zhao Fang , Real Birgit , Heeke Christina , Bielefeld Nicola , Maβen Stefan , Horn Susanne , Moll Iris , Maltaner Raffaela , Horn Peter A. , Schilling Bastian , Sabbatino Francesco , Lennerz Volker , Kloor Matthias , Ferrone Soldano , Schadendorf Dirk , Falk Christine S. , Griewank Klaus , Paschen Annette
Published: April 2023

Supplementary Methods
Supplementary Fig. S6 from Genetic Evolution of T-cell Resistance in the Course of Melanoma Progression
Authors: Sucker Antje , Zhao Fang , Real Birgit , Heeke Christina , Bielefeld Nicola , Maβen Stefan , Horn Susanne , Moll Iris , Maltaner Raffaela , Horn Peter A. , Schilling Bastian , Sabbatino Francesco , Lennerz Volker , Kloor Matthias , Ferrone Soldano , Schadendorf Dirk , Falk Christine S. , Griewank Klaus , Paschen Annette
Published: April 2023

Supplementary Fig. S6. A, Analysis of HMB-45 (melanoma cells) and HLA class I antigen expression in serial sections from cryopreserved metastasis Ma-Mel-100b. Positive cells stain red. B, Localization of the 12 bp deletion in the B2M gene of Ma-Mel-100b cells. Capital letters (upper line) indicate the β2m amino acid sequence (aa), small letters (lower line) the nucleotide sequence of the corresponding B2M gene region (nt). Numbers indicate the aa position within the protein sequence.
Supplementary Fig. S4 from Genetic Evolution of T-cell Resistance in the Course of Melanoma Progression
Authors: Sucker Antje , Zhao Fang , Real Birgit , Heeke Christina , Bielefeld Nicola , Maβen Stefan , Horn Susanne , Moll Iris , Maltaner Raffaela , Horn Peter A. , Schilling Bastian , Sabbatino Francesco , Lennerz Volker , Kloor Matthias , Ferrone Soldano , Schadendorf Dirk , Falk Christine S. , Griewank Klaus , Paschen Annette
Published: April 2023

Supplementary Fig. S4. Real-time proliferation of Ma-Mel-48 cell lines was determined in an xCelligence device. 1,5 x 104 cells were seeded per well and proliferation was determined over time. Representative data from one of three independent experiments are depicted
Supplementary Table 5 from IL2 Inducible T-cell Kinase, a Novel Therapeutic Target in Melanoma
Authors: Carson Craig C. , Moschos Stergios J. , Edmiston Sharon N. , Darr David B. , Nikolaishvili-Feinberg Nana , Groben Pamela A. , Zhou Xin , Kuan Pei Fen , Pandey Shaily , Chan Keefe T. , Jordan Jamie L. , Hao Honglin , Frank Jill S. , Hopkinson Dennis A. , Gibbs David C. , Alldredge Virginia D. , Parrish Eloise , Hanna Sara C. , Berkowitz Paula , Rubenstein David S. , Miller C. Ryan , Bear James E. , Ollila David W. , Sharpless Norman E. , Conway Kathleen , Thomas Nancy E.
Published: April 2023

Supplementary Table 5. BI 10N kinase selectivity at ATP concentrations of approximate Km for ATP and 1 mM ATP
Supplementary Table 2 from IL2 Inducible T-cell Kinase, a Novel Therapeutic Target in Melanoma
Authors: Carson Craig C. , Moschos Stergios J. , Edmiston Sharon N. , Darr David B. , Nikolaishvili-Feinberg Nana , Groben Pamela A. , Zhou Xin , Kuan Pei Fen , Pandey Shaily , Chan Keefe T. , Jordan Jamie L. , Hao Honglin , Frank Jill S. , Hopkinson Dennis A. , Gibbs David C. , Alldredge Virginia D. , Parrish Eloise , Hanna Sara C. , Berkowitz Paula , Rubenstein David S. , Miller C. Ryan , Bear James E. , Ollila David W. , Sharpless Norman E. , Conway Kathleen , Thomas Nancy E.
Published: April 2023

Supplementary Table 2. Staining protocols for antibodies utilized for immunohistochemistry throughout the study
Supplementary Figure legends from IL2 Inducible T-cell Kinase, a Novel Therapeutic Target in Melanoma
Authors: Carson Craig C. , Moschos Stergios J. , Edmiston Sharon N. , Darr David B. , Nikolaishvili-Feinberg Nana , Groben Pamela A. , Zhou Xin , Kuan Pei Fen , Pandey Shaily , Chan Keefe T. , Jordan Jamie L. , Hao Honglin , Frank Jill S. , Hopkinson Dennis A. , Gibbs David C. , Alldredge Virginia D. , Parrish Eloise , Hanna Sara C. , Berkowitz Paula , Rubenstein David S. , Miller C. Ryan , Bear James E. , Ollila David W. , Sharpless Norman E. , Conway Kathleen , Thomas Nancy E.
Published: April 2023

Legends for Supplementary Figures 1 and 2
Supplementary Materials and Methods from Wee-1 Kinase Inhibition Sensitizes High-Risk HPV+ HNSCC to Apoptosis Accompanied by Downregulation of MCl-1 and XIAP Antiapoptotic Proteins
Authors: Tanaka Noriaki , Patel Ameeta A. , Wang Jiping , Frederick Mitchell J. , Kalu Nene N. , Zhao Mei , Fitzgerald Alison L. , Xie Tong-xin , Silver Natalie L. , Caulin Carlos , Zhou Ge , Skinner Heath D. , Johnson Faye M. , Myers Jeffrey N. , Osman Abdullah A.
Published: April 2023

Analysis of combined drug effects; Immunofluorescence; Caspase-Glo 3/7 activity assay; Quantitative reverse-transcriptase PCR (qRT-PCR); Orthotopic Mouse Model of Oral Cavity Cancer and Tumor Growth Delay; Generation of patient-derived HNSCC xenografts and treatment with AZD-1775; Immunohistochemistry; and In vivo TUNEL assay.
Supplementary Materials and Methods from The New Antitumor Drug ABTL0812 Inhibits the Akt/mTORC1 Axis by Upregulating Tribbles-3 Pseudokinase
Authors: Erazo Tatiana , Lorente Mar , López-Plana Anna , Muñoz-Guardiola Pau , Fernández-Nogueira Patricia , García-Martínez José A. , Bragado Paloma , Fuster Gemma , Salazar María , Espadaler Jordi , Hernández-Losa Javier , Bayascas Jose Ramon , Cortal Marc , Vidal Laura , Gascón Pedro , Gómez-Ferreria Mariana , Alfón José , Velasco Guillermo , Domènech Carles , Lizcano Jose M.
Published: April 2023

Supplementary Materials and Methods
Supplementary Figure S9 from Wee-1 Kinase Inhibition Sensitizes High-Risk HPV+ HNSCC to Apoptosis Accompanied by Downregulation of MCl-1 and XIAP Antiapoptotic Proteins
Authors: Tanaka Noriaki , Patel Ameeta A. , Wang Jiping , Frederick Mitchell J. , Kalu Nene N. , Zhao Mei , Fitzgerald Alison L. , Xie Tong-xin , Silver Natalie L. , Caulin Carlos , Zhou Ge , Skinner Heath D. , Johnson Faye M. , Myers Jeffrey N. , Osman Abdullah A.
Published: April 2023

Apoptosis is absent in vivo in an orthotopic mouse model of oral tongue bearing HPV negative HNSCC tumor cells treated with AZD-1775 and cisplatin.
Supplementary Figures from The New Antitumor Drug ABTL0812 Inhibits the Akt/mTORC1 Axis by Upregulating Tribbles-3 Pseudokinase
Authors: Erazo Tatiana , Lorente Mar , López-Plana Anna , Muñoz-Guardiola Pau , Fernández-Nogueira Patricia , García-Martínez José A. , Bragado Paloma , Fuster Gemma , Salazar María , Espadaler Jordi , Hernández-Losa Javier , Bayascas Jose Ramon , Cortal Marc , Vidal Laura , Gascón Pedro , Gómez-Ferreria Mariana , Alfón José , Velasco Guillermo , Domènech Carles , Lizcano Jose M.
Published: April 2023

Powerpoint file containing Supplementary Figures 1, 2, 3, 4, 5, 6 and 7
Supplementary Figure S1 - S2 from Wee-1 Kinase Inhibition Sensitizes High-Risk HPV+ HNSCC to Apoptosis Accompanied by Downregulation of MCl-1 and XIAP Antiapoptotic Proteins
Authors: Tanaka Noriaki , Patel Ameeta A. , Wang Jiping , Frederick Mitchell J. , Kalu Nene N. , Zhao Mei , Fitzgerald Alison L. , Xie Tong-xin , Silver Natalie L. , Caulin Carlos , Zhou Ge , Skinner Heath D. , Johnson Faye M. , Myers Jeffrey N. , Osman Abdullah A.
Published: April 2023

Supplementary Figure S1. Conservative isobologram plots showing the synergistic interactions of cisplatin and AZD-1775 in HPV+ HNSCC cells; and Supplementary Figure S2. Wee-1 kinase inhibition triggers persistent DNA damage response associated with impaired homologous recombination in HPV+ HNSCC cells.